The long-term international safety experience of imiglucerase therapy for Gaucher disease

Molecular Genetics and Metabolism

Volumn 90, Issue 2, 2007, Pages 157-163

  Starzyk, Kathryn ^a   Richards, Susan ^a   Yee, John ^a   Smith, Sharon E ^a   Kingma, Wytske ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

Gaucher disease; Glucocerebrosidase; Safety

Indexed keywords

ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; IMIGLUCERASE; IMMUNOGLOBULIN G ANTIBODY;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANXIETY; ARTICLE; ASTHENIA; BREAST DISEASE; CHEST TIGHTNESS; CHILL; CHOLELITHIASIS; CONGENITAL DISORDER; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DATA BASE; DEPRESSION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EAR DISEASE; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; EYE DISEASE; FATIGUE; FLUSHING; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; GENITAL SYSTEM DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INFECTION; INFORMATION PROCESSING; INJECTION SITE REACTION; INNER EAR DISEASE; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PREGNANCY DISORDER; PRIORITY JOURNAL; PRURITUS; RADIOIMMUNOPRECIPITATION; REPRODUCTIVE TOXICITY; SEROCONVERSION; SIDE EFFECT; SKIN DISEASE; THORAX PAIN; THROAT IRRITATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY TRACT DISEASE; URTICARIA; VASCULAR DISEASE; VOMITING;

DRUG APPROVAL; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; LONGITUDINAL STUDIES;

EID: 33846197993     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2006.09.003     Document Type: Article

References (24)

1. Brady R.O., Kanfer J., and Shapiro D. The metabolism of glucocerebrosides. I. Purification and properties of a glucocerebroside-cleaving enzyme from spleen tissue. J. Biol. Chem. 240 (1965) 39-43
2. Rosenberg M., Kingma W., Fitzpatrick M.A., and Richards S.M. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93 (1999) 2081-2088
3. W. Kingma, E. Chadbourne, R. Cintron, S. Richards, G.C. Cox, Safety and immunogenicity of recombinant enzyme replacement therapy for lysosomal storage disorders, Am. Soc. Hum. Genet. Annual Meeting.
4. Cerezyme Package Insert, Genzyme Corporation, April 2005.
5. K. Starzyk, W. Kingma, Long term international safety monitoring of enzyme replacement therapy in Gaucher disease, Am. Soc. Hum. Genet. Meeting 2003.
6. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., and Brady R.O. Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann. Intern. Med. 122 (1995) 33-39
7. Richards S.M., Olson T.A., and McPherson J.M. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood 82 (1993) 1402-1409
8. Kingma W. Gaucher disease: an overview of clinical characteristics and therapy. J. Intraven. Nurs. 19 (1996) 79-82
9. Frasier S.D., Aceto Jr. T., Hayles A.B., Parker M.L., and Meyer-Bahlburg H.F. Collaborative study of the effects of human growth hormone in growth hormone deficiency. II. Development and significance of antibodies to human growth hormone during the first year of therapy. J. Clin. Endocrinol. Metab. 38 (1974) 14-18
10. Ross J.M. Allergy to insulin. Pediatr. Clin. North Am. 31 (1984) 675-687
11. Figlin R.A., deKernion J.B., Mukamel E., Palleroni A.V., Itri L.M., and Sarna G.P. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J. Clin. Oncol. 6 (1988) 1604-1610
12. Crowe J.S., Gewert D.R., Barber K.A., Lewis A.P., Sims M.J., Davies S.L., Salom C.L., Wood J., Thomas H.C., and Thursz M. Interferon (IFN)-alpha 2 genotype analysis of Chinese chronic hepatitis B patients undergoing recombinant IFN-alpha 2a therapy. J. Infect. Dis. 169 (1994) 875-878
13. Brooks D.A., Kakavanos R., and Hopwood J.J. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol. Med. 9 (2003) 450-453
14. Roberts H.R., and Cromartie R. Overview of inhibitors to factor VIII and IX. Prog. Clin. Biol. Res. 150 (1984) 1-18
15. Knobler R.L., Greenstein J.I., Johnson K.P., Lublin F.D., Panitch H.S., Conway K., Grant-Gorsen S.V., Muldoon J., Marcus S.G., and Wallenberg J.C. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J. Interferon. Res. 13 (1993) 333-340
16. Allegretta M., Atkins M.B., Dempsey R.A., Bradley E.C., Konrad M.W., Childs A., Wolfe S.N., and Mier J.W. The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J. Clin. Immunol. 6 (1986) 481-490
17. Schellekens H. Immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 18 (2003) 1257-1259
18. Bennett C.L., Cournoyer D., Carson K.R., Rossert J., Luminari S., Evens A.M., Locatelli F., Belknap S.M., McKoy J.M., Lyons E.A., Kim B., Sharma R., Costello S., Toffelmire E.B., Wells G.A., Messner H.A., Yarnold P.R., Trifilio S.M., Raisch D.W., Kuzel T.M., Nissenson A., Lim L.C., Tallman M.S., and Casadevall N. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 106 (2005) 3343-3347
19. Rader R.A. Biopharmaceutical Products in the US and European Markets (2005), Bioplan Associates, Inc, Maryland
20. F.J. Grogan, R.E. Pearson, C. Connor (Eds.), in: Mosby's Drug Consult 2006 February Update, Mosby, Inc, Missouri.
21. Approved Biotechnology Drugs. BIO. January 20, 2006. Available from: .
22. Therapeutic Biological Products Approvals. Updated: December 12, 2003. FDA. February 20, 2006. Available from: .
23. Drugs @ FDA. August 2, 2006. Available from: .
24. List of Authorized Products (EPARS). EMEA. February 21, 2006. Available from: .